Celltrion announced a mid-to-long-term policy to allocate approximately one-third of annual consolidated net income to shareholder returns and approved a ₩100 billion ($72 million) share buyback. On-market purchases of 524,384 shares will begin Sept. 1, with the acquired shares planned for cancellation after required procedures. Including the latest decision, Celltrion’s buybacks approved this year total 1,600,288 shares worth approximately ₩300 billion, while repurchases over the past three years have reached about 8.93 million shares. The company will choose between cash dividends and buybacks followed by cancellations based on share-price levels, market conditions, its financial structure, cash flow and investment plans. It may pursue additional buybacks and cancellations if the gap between its share price and corporate value is considered significant. Celltrion said biosimilar prescription growth in the United States and Europe and market stabilization of new high-margin products will support both investment and shareholder returns.